Novel recombinant oncolytic vaccinia virus for blocking immune inspection point and activating immune co-stimulation, construction method for novel recombinant oncolytic vaccinia virus and application of Novel recombinant oncolytic vaccinia virus
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- NANJING VIROTHER BIOPHARMACEUTICAL CO LTD
- Publication Date
- 2020-12-18
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of tumor biotechnology, in particular to a novel recombinant oncolytic vaccinia virus that blocks immune checkpoints and activates immune co-stimulatory signaling pathways, and its construction method and application. Background technique
[0002] Cancer is one of the most harmful diseases to human life and health, and millions of people die of cancer every year. Many patients are already in the middle and late stage at the time of diagnosis and thus lose the chance of surgical treatment. Traditional radiotherapy and chemotherapy have not made breakthroughs, and even small-molecule targeted drugs are still facing the huge challenge of short-term recurrence.
[0003] In the past ten years, exciting results have emerged in the clinical research of anti-tumor immunotherapy, bringing hope to cancer patients again. As early as 1090, German scientist (Nobel Prize winner) Paul Ehrlich proposed that the immune system has th...